Comparative performances of nomograms and conditional survival after resection of adrenocortical cancer BJS Open, 2021, 5(1), zraa036 Click here to read the study  

Due to the continued risk from the Coronavirus pandemic, the 2021 Annual Patient Information Day has been moved from May to October.   Click here for more information  

We have gathered together as many useful resources as possible to help you through the 2nd wave of COVID-19.  Despite working from home, our staff are all available to you as usual. Click here to learn more

We are delighted that we have received a grant from the National Lottery Emergency Coronavirus Community Fund to support our members’ free Counselling Service for the next 12 months.  The service, which has no waiting list, provides personal Counselling to any registered member who’s struggling emotionally.

AMEND is undertaking a year-long study into the impact of COVID-19 on the mental health of those who live with ACC in the UK.  Answers to the survey are anonymous and data will be shared appropriately to help guide potential improvements in care for the future.  Thank you for your help. Click here to take the survey

ACC Support recently worked with Health Awareness on the 2020 Rare Disease campaign. A printed publication was enclosed within every copy of the New Scientist and the content is available online at https://bit.ly/35OVrCe  . The campaign featured exclusive content from key thought leaders and, discussed the impact and sign and symptoms of Adrenocortical Cancer (ACC).    

The results of the prospective EURINE-ACT study were published in The Lancet at 11:30pm on Thursday 23rd July, 2020.  The study, led by Professor Wiebke Arlt (IMSR Birmingham), involved 14 specialist centres in 11 countries, and 2169 participants (recruited between 2011 and 2016).  It has been successful in validating a new urine steroid metabolomics test for earlier diagnosis of ACC.  The study recommended changes in CT imaging practice and ultimately ‘a triple test strategy of tumour diameter, imaging characteristics, and urine steroid metabolomics’ to improve Continue reading →

On Saturday 26th November 2016, ACC Support UK, in collaboration with ENS@T (the European Network for the Study of Adrenal Tumours), invites all patients and carers affected by adrenocortical cancer to our second free patient information event.  There is a great opportunity to attend a series of short scientific presentations in the morning which form part of the ENS@T meeting.  Alternatively, there is a later registration option for those who wish to attend the patient sessions only.  The full day runs from 08:30-15:30 and includes lunch Continue reading →

Professor Arlt describes the treatments used for adrenocortical cancer with emphasis on the need for an expert multidisciplinary team (MDT)